Tarceva 100 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Erlotinib |
| Company | Roche bangladesh ltd |
| Also available as |
Title
Tarceva Tablet
Categories
- Cancer Treatment
- Cell Lung Cancer Medication
- Pancreatic Cancer Medication
- Kinase Inhibitor
Description
Tarceva is a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine. Tarceva reversibly inhibits the kinase activity of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor and thereby inhibiting further downstream signaling. Tarceva binding affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations is higher than its affinity for the wild-type receptor. Tarceva inhibition of other tyrosine kinase receptors has not been fully characterized.
DosageAndAdministration
- RecommendedDailyDose:
- NSCLC: 150 mg on an empty stomach
- PancreaticCancer: 100 mg once daily in combination with gemcitabine
- DosageAdjustments:
- Reduce Erlotinib by 50 mg decrements with concomitant use of strong CYP3A4 inhibitors
- Increase Erlotinib by 50 mg increments as tolerated for concomitant use with CYP3A4 inducers
Interactions
- Anticoagulants: Can lead to increased International Normalized Ratio (INR) and bleeding adverse reactions
- CYP3A4Inhibitors: Metabolized predominantly by CYP3A4
- CYP3A4Inducers: Pre-treatment with CYP3A4 inducer Rifampicin for 7-11 days prior to Tarceva decreased Tarceva AUC by 58% to 80%
- DrugsAffectingGastricPH: Co-administration with omeprazole decreased Tarceva AUC by 46%
SideEffects
- Rash
- Diarrhea
- Anorexia
- Fatigue
- Dyspnea
- Cough
- Nausea
- Vomiting
- Interstitial Lung Disease (ILD)
PregnancyAndLactation
Pregnancy category D. Can cause fetal harm when administered to a pregnant woman
PrecautionsAndWarnings
- Interstitial Lung Disease (ILD) occurs in 1.1% of patients
- Renal Failure: Monitor renal function and electrolytes
- Hepatotoxicity with or without hepatic impairment
SpecialPopulations
- PediatricUse: Safety and effectiveness not established
- GeriatricUse: No overall differences in safety or efficacy observed between subjects 65 years and older and those younger than 65
OverdoseEffects
- Effects: In case of suspected overdose, symptomatic treatment instituted
TherapeuticClass
Targeted Cancer Therapy
StorageConditions
Store at a temperature not exceeding 30°C in a dry place. Protect from light and moisture